This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
EAU 2024
EAU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
EAU 2024 Prostate Cancer
Viewing 21-40 of 53 articles
EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: No
EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: The Guidelines' View
EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: Yes
EAU 2024: Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL-PSMA-PET/CT Scans in Pre-Treatment Prostate Cancer Patients
EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + Risk Calculators + MRI (The EAU Screening Algorithm)
EAU 2024: PSMA-PET Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: a Phase 2 Randomized Controlled Trial
EAU 2024: Three-Year Oncological Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer
EAU 2024: PSICHE Trial: PSMA Guided Approach for Biochemical Relapse After Prostatectomy- a Prospective Trial
EAU 2024: Two-Year Quality of Life (QoL) Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer
EAU 2024: Identifying the Optimal Definition of PSA Response After Metastasis Directed Therapy in Men with Oligo-Recurrent Prostate Cancer Detected at PSMA PET
EAU 2024: Avoiding Overtreatment using PSA Doubling Time Kinetics: Long-Term Management of BCR Following RARP
EAU 2024: PIONEER: Development of a Predictive Model for Death Amongst Patients with mHSPC Treated with One of the Approved Treatment Plans Based on Characteristics Present at Admission Using Big Data
EAU 2024: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel in European Patients from the Phase 3 ARASENS Trial
EAU 2024: Impact of Disease Volume on Survival Efficacy of Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
EAU 2024: Familial Prostate Cancer: Does It Influence the Screening and Management?
EAU 2024: PARP Inhibitor Plus Androgen Receptor Pathway Inhibitor Combinations for 1st Line mCRPC: A Systematic Review and Meta-Analysis
EAU 2024: Comparison of Biparametric and Multiparametric MRI for Prostate Cancer Detection: The PRIME Study
EAU 2024: PEACE V – Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM): 24-Months Toxicity Results of a Randomized Phase II Trial
EAU 2024: Early Oncological Outcomes Following Radical Prostatectomy of Patients with Pelvic Lymph Node-Positive Prostate Cancer at Preoperative PSMA PET/CT
EAU 2024: Neoadjuvant Pamiparib plus Abiraterone and ADT for High-Risk/very High-Risk Localized Prostate Cancer: Results of a Prospective Study
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free